Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Peripheral residual disease activity assessment by MALDI-TOF mass spectrometry in patients with newly-diagnosed multiple myeloma in the GMMG-HD7 study

View Full Paper
Ask AI
Bookmark
Share

Authors

RSRoland SchroersIBIgor Wolfgang BlauSLSteffen Luntz

Discussion

Loading...

Member takes

Overview

Peripheral residual disease assessment indicates significant prognostic value for progression free survival in newly-diagnosed multiple myeloma.

Key Points

  • Peripheral residual disease assessment showed significant prognostic value for progression free survival in multiple myeloma.
  • Post induction, 22% of patients achieved minimal residual disease negativity, correlating with improved outcomes.
  • Using mass spectrometry, the study analyzed serum samples from patients at various stages, including post autologous stem cell transplant.
  • This highlights the potential of mass spectrometry as a minimally invasive method for tracking disease progression.

Cite This Study

Schroers et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc86https://doi.org/10.1182/blood-2025-920
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Minimally invasive assessment of peripheral residual disease (PRD) during maintenance or observation in patients (Pts) with multiple myeloma (MM): An update from the GEM2017FIT clinical trial2025
  2. 2Sensitive peripheral residual disease (PRD) detection using clonotypic mass spectrometry (EasyM) in patients with newly diagnosed multiple myeloma (NDMM)2025
  3. 3Patterns of minimal residual disease trajectories in 323 newly diagnosed patients with multiple myeloma and correlation with progression-free survival2025
  4. 4Measurable residual disease in newly diagnosed multiple myeloma: Experience from a large cohort from an academic medical center2025
  5. 5What remains matters: Real-world impact of measurable residual disease testing in multiple myeloma2025